The year 2007 saw record numbers of WNVI in Canada. The PHAC reported one case in Nova Scotia, two in Quebec, 12 in Ontario, 578 in Manitoba, 1285 in Saskatchewan, 318 in Alberta and 19 in BC 3 . This study focuses on the clinical description of the neuroinvasive West Nile infection (NWNI) of West Nile infection reported in 2007 in the Saskatoon Health Region (SHR).
METHODS

Objective: To review the large outbreak of West Nile infection in Canada, focusing on the cases of NWNI in the SHR
Source of information: West Nile Virus national surveillance is a collaborative effort between the PHAC, provincial and territorial Ministries of Health, the Canadian Cooperative Wildlife Health Centre, Health Canada's First Nations and Inuit Health Branch, Canadian Blood Services, and Héma-Québec 3 . Since 2003 the government of Canada and provincial health regions have reported and collected epidemiological data about the number of cases per year, in order to identify risk factors and promote prevention. The province of Saskatchewan experienced its first ever outbreak of WNV during the summer of 2003, recording 937 clinically confirmed cases of WNV. Eight hundred and fifty eight (91%) cases manifested as West Nile Fever (WNF), 63 (7%) as NWNI, 10 (1%) were asymptomatic, and 16 (1%) cases were categorized with unknown manifestation. For this report we used the information reported by the government of Saskatchewan and the government of Canada using the West Nile Virus national surveillance.
Case diagnostic test criteria: We used the standard criteria composed by the PHAC, which is the detection of flavivirus antibodies in a single serum or cerebrospinal fluid (CSF) sample using a WNV IgM ELISA without confirmatory neutralization serology (e.g. Plaque Reduction Neutralization Test -PRNT) 3 . Case definition for NWNI. For the purpose of this study, the Saskatoon Health Region (SHR) provided the researchers with a list of 71 cases with potential WNI who were admitted one of three Saskatoon hospitals in 2007. Not all patients that were admitted to the hospital necessarily had NWNI. Some of them were admitted because of other medical reason but had positive serology. This initial list allowed us to identify all the potential cases with NWNI. The cases were reviewed by a neurology resident who was specifically trained to perform data extraction. Cases were discussed with two neurologists and a final classification was performed. To define a case of NWNI, we use the definition of the PHAC 3 . The definition for NWNI in our series was as follows: a) History of exposure in an area where WNV activity is occurring b) or history of exposure to an alternative mode of transmission and c) onset of fever. In addition to this criteria a recent onset of at least one of the following: 1) encephalitis (acute signs of central or peripheral neurological dysfunction), 2) or viral meningitis (pleocytosis and signs of infection e.g., headache, nuchal rigidity), 3) or acute flaccid paralysis (e.g., poliomyelitis-like syndrome or GuillainBarre-like syndrome), 4) Movement disorders (e.g., tremor, myoclonus), 5) or Parkinsonism or Parkinsonian-like conditions (e.g., cogwheel rigidity, bradykinesia, postural instability). Other emerging clinical syndromes were considered such as: myelopathy, rhabdomyolysis, peripheral neuropathy; polyradiculoneuropathy; optic neuritis; and acute demyelinating encephalomyelitis (ADEM). All the charts were reviewed in order to apply the definition. Fifty-seven (80%) cases met criteria for NWNI and the rest were classified as West Nile fever. Cases with NWNI: 57 cases met criteria for NWNI. Thirty nine (68%) were females. Nine (16%) patients were camping, two (4%) reported outdoor sports and four (8%) reported outdoor activities. The rest of patients did not perform any outside activity. Nine (16%) patients had diabetes, 11(19%) renal failure, 4 (7%) chronic obstructive pulmonary disease (COPD) 2 (4%), hypertension, and 2 (4%) had some form of immunosuppression. Sixteen patients (28%) were smokers and 7 (12%) were alcoholics. Overall the rate of NWNI using the review of the charts and applying criteria was 16%, compared with the 10% reported by the government of Saskatchewan. Timing ( Figure 3 ): One (2%) case appeared in June, one (1.8%) in July, 47 (82%) in August, five (9%) in September, two (4%) in October and one (2%) in November. General symptoms: 44 (77%) patients had fever, 19 had neck stiffness (33%), 18 had weakness (32%), 18 had shivers or rigors (32%), 10 had myalgias (18%), 16 had rash (28%), 29 had malaise (51%), 7 had weight loss (12%), 29 had vomiting (51%), and 31 had nausea (54%). This report is based on the largest outbreak of cases since 2003, and will serve as an important building block for future epidemiologic studies of NWNV in North America and elsewhere. There are no large descriptive studies of NWND in Canada to date. The outbreak in Saskatchewan was the largest reported since the first death was reported in Canada in 1999. The Government of Saskatchewan surveillance program reported that 10% of cases of West Nile fever developed NWND. In our study the percentage of cases with NWND approaches 16%. The main reason for this discrepancy probably relates to case definitions and ascertainment strategies. We reviewed the charts from all patients admitted to our center with suspicion of NWND, and with careful application of accepted criteria by neurologists, we were able to identify additional cases.
RESULTS
Outbreak in
In the US, the rates of NWND are variable; for example in 1999 it was 59%, 2000 19%, 2011 64%, with an average percentage of 40.3 between 1999 and 2007 2 . In Canada the rates of NWNI are also variable ( Figure 5 ) between 9.7 and 52%. The reported rates in Saskatchewan are lower compared to the national rate. This could be related to regional predisposition in patients across the different Canadian provinces. Interestingly the percentage of NWND is not dependent on sample size, being higher in years where the overall number of WNV cases was stable or lower than previous.
The range of symptoms associated with WNVI extends from uncomplicated febrile illness to meningitis, neuropathies, muscle weakness, paralysis, and encephalitis. Symptoms generally become apparent 2-14 days after infection by mosquito bite. Approximately 80% of infected individuals are asymptomatic. The majority of symptomatic patients present with flu-like symptoms. NWND syndromes include meningitis, encephalitis, and acute flaccid paralysis. Movement disorders including Parkinsonism, tremor, dyskinesias, and myoclonus can be seen. Opsoclonus has also been reported 6, 7 . Sejvar et al 8 reported the neurological manifestation in 16 patients with NWND from 39 suspected cases. Five (31%) patients had meningitis, 8 (50%) had encephalitis, 3 (19%) acute flaccid paralysis, 15 (94%) patients tremor, myoclonus in 5 (31%) and Parkinsonism in 11 (69%). One patient died, but overall all the patients had a favourable outcome. Our study showed a high percentage of patients with meningitis, encephalitis or meningoencephalitis as was expected, being one of the most common manifestations of NWNI. Our study showed that 32% of patients had tremor. Postural and kinetic tremor has been reported as a feature of adult West Nile virus encephalitis in 10 to 50% of cases, and in the majority of cases the tremor disappears over few months 8, 9 . Acute flaccid paralysis has been reported in in 50 to 80% of patients with West Nile virus encephalitis 10 , which can manifest as a Guillain Barre type syndrome, or resemble polio/anterior horn cell disease 10 . In our cohort the majority of patients had a Guillain-Barre type paralysis that resolved in a few weeks. Only one patient had persistent weakness that was treated with IVIG. Our study is the first in Canada describing the clinical manifestations of NWNI in the largest outbreak reported in Canada and in a single province. The early recognition of neurological signs in cases of WNVI is of significant public health and epidemiologic importance. The rates of WNVI have fluctuated widely and unpredictably over the last decade, and certainly new outbreaks are expected, as evidenced by a small resurgence in 2012 3 . While treatment is mainly supportive, improved understanding of mechanisms and risks for NWNI will be beneficial for development of prevention strategies and optimizing treatment, in addition to improving the accuracy of prognostication. Overall our patients had a good prognosis with a low mortality (5%) in agreement with other studies 8 . Proposed risk factors for West Nile disease include age (between 40 and 50 years), diabetes, chronic renal disease, race/ethnicity (being black) and possibly a history of hypertension or cardiovascular disease 11, 12 . Outdoor activity without the use of personal protective clothing, particularly during the high-risk periods of dawn and dusk, and exposure in areas that provide a conducive environment for mosquito breeding, have been shown to be important risk factors for contracting WNV 13 . A serosurvey conducted in New York City after the outbreak of West Nile encephalitis in 1999, found that individuals who spent more than two hours outdoors after dusk or dawn (peak biting periods for the Culex mosquito genus), and persons who did not use the insect repellant diethyltoluidine (DEET) had the highest rates of West Nile 15 virus seroprevalence 14 . They also found that having seen a dead bird in one's neighbourhood was associated with a higher rate of infection 14 . A 1996 study in Romania concluded that risk of infection was significantly higher for apartment dwellers with flooded basements 15 . One of the limitations of our study is the lack of a comparison group of patients with asymptomatic disease in order to identify risk factors. Even with the lack of a control group, our patients appeared to have similar comorbidities to those reported in the literature, including diabetes, hypertension and immunosuppression. The timing of NWNI in our study supports outdoor activity as a risk factor.
Neurological manifestations identified in our study provide very useful information for physicians working in NorthAmerica and around the world. The recognition of neurological symptoms and syndromes is very relevant to improve the diagnosis and treatment of patients. The cases of WNVI fluctuate every year and have been low for the last four years, probably related to government campaigns to prevent WNI, which is directly related to the establishment of the surveillance program by the Government of Canada. The rates of NWNI also change every year in Canada and do not depend of the number of cases per year. Neurological manifestations such as tremor and acute paralysis should be recognized by physicians in Canada in order to optimize and improve supportive treatment. This report is based in the largest outbreak in Canada and focused in a single province, serving as foundational information for future descriptions in Canada and internationally.
